Oral Oncolytics and Cardiovascular Risk Management and Monitoring.
Raechel T WhiteMarie E SirekJoel C MarrsPublished in: Journal of cardiovascular pharmacology (2023)
Oral oncolytic treatment options have expanded over the last decade and have brought to light the need to monitor and manage cardiovascular (CV) disease in patients being treated with these therapies. There is a need to assess CV risk before patients receive oral oncolytic therapy with known potential to cause negative CV sequelae such as left ventricular dysfunction, hypercholesterolemia, hypertension, and arrhythmias. The review highlights the need to evaluate traditional CV risk factors and their association with the development and progression of cancer. Additionally, this review suggests approaches to monitor for CV adverse events and manage CV disease during and after treatment with oral oncolytic therapy. Key guideline recommendations are reviewed and highlight specific approaches to minimize CV harm for patients exposed to oral oncolytic therapy. Careful monitoring and patient-centered decision making is key in choosing appropriate therapies. A multidisciplinary approach between oncologists, cardio-oncologists, pharmacists, and other members of the healthcare team is essential in navigating cardiac toxicities.
Keyphrases
- end stage renal disease
- newly diagnosed
- left ventricular
- healthcare
- ejection fraction
- chronic kidney disease
- risk factors
- heart failure
- prognostic factors
- decision making
- squamous cell carcinoma
- type diabetes
- cardiovascular disease
- palliative care
- patient reported outcomes
- quality improvement
- climate change
- mesenchymal stem cells
- cardiovascular events
- clinical practice
- young adults
- patient reported
- aortic stenosis
- aortic valve
- cell therapy
- smoking cessation
- general practice
- breast cancer risk